Altered peripheral vesodilator profile of nitroglycerin during long-term infusion of N-acetylcysteine  by Boesgaard, Søren et al.
JACC Vol. 23, No . I
January 1994 : 1 6 3-9
Objectives. The aim of this study was to compare the short- and
long-term effects of intravenous nitroglycerin plus placebo and
nitroglycerin plus N-acetylcysteine on peripheral arteries, valets
and microcircttlation in humans,
Background . The thiol dottier .Naacetylcysteine may potentiate
the hemodynatmic response to nitrates in nitrate-tolerant and
aantoleraat patients . The vas-colar changes responsible for this
effect are not clear .
Methods. Eight male volunteers were treated with nitroglycerin
(0,1 sg/ per mire) combined with N-acetylcysteine (2 g intrave-
nously, followed by 5 mg/kg per h) or placebo for 23 h in a
double-blind, randomized, crossover study. Venous volume, the
diameter of the radial and temporal arteries, calf blood flow and
subcutaneous blood flow were measured at baseline and repeated
after I and 23 Ia of infusion .
Results . Prolonged coadtninistration of N-acetylcysleine and
nitroglycerin potentiated the acute venodilator effect of nitroglyc-
erin as estimated by changes in venmas volume (nitroglycerin plus
N-acetylcysteine, 4.45 ± 0.36 seal/100
g;
nitroglycerin plus placebo,
Organic nitrates are potent vasodilators . However, continu-
ous exposure to these compounds causes a rapid attenuation
of their hemodynamic and clinical effects (1-3) . Currently,
the specific response of the different vascular beds to pro-
longed nitroglycerin administration in humans and thus their
contribution to the development of tolerance are not clear .
The metabolic activation of nitroglycerin to vasoactive
intermediates (nitric oxide or S-nitrosothiols, or both) re-
quires an interaction with thiol compounds like cysteine and
glutathione (4,5) . In accordance with this finding, the thiol
donor N-acetylcysteine has been shown to potentiate the
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3.65 ± 0.46 rni/100 g, mean ± SEM, p < 0 .05) and prevented
development of tolerance as seen after 23 h of treatment with
nitroglycerin
plus placebo (4.35 ± 0.25 vs . 3 .47 ± 0 .41 nit/100 g,
p < 0.05) . N-acetylcystehae had no effect on nitroglycerin-induced
changes in ari rial diameters (p > 0.05) but significantly increased
aticrocirculatory subcartaneous blood flow after I It (nitroglycerin
plus '-acetyicysteinco 6. 7, ± 1.3 mV100
g
per -sin vs . nitroglycerin
plus placebo: 3 .5 ® 0 .3 m11160 g per min, p < 0 .051 and after 23 It
(4.4±0.6vs.3.1±0.5 MINI) gpermin,p<0 .05) .
Conclusions . The results suggest that coadministratloaa of
nitroglycerin and N-aeetytcystehte in humans t) potentiates and
preserves nitroglycerin-induced veatodilatioaa and 2) augments the
effect of nitroglycerin on small resistance vessels (regulating
subcutaneous blood fovw) without affecting the response to nitro-
glycerin in middle-sized arteries . Both the development of nitrate
tolerance and the administration of N-acelylcysteine significantly
change the normal vasodilator pro -file of nitroglycerin in hung ans .
(J Am Coll Cardiol 1994;23 :T63-9)
hemodynamic effects of nitrates in the nontolerant (6,71 and
tolerant state (8-10) and partially to prevent tolerance de-
velopment to nitrate-induced antianginal effects (I1) . How-
ever, a general agreement on the vascular changes respon-
sible for the effect of thiol supplementation has not been
reached. Some studies (10,12,13) report a thiol-mediated
effect on the venous vascular bed, whereas other results
(6,7,9,14) are compatible with an effect on the arterial side of
the circulation as well . In addition, based on findings in the
coronary circulation of animals, it has recently been hypoth-
esized that the peripheral effect of thiol supplementation
results from dilation of small resistance vessels only respon-
sive to nitroglycerin in the presence of exogenous cysteine
(15,16) .
The present study was performed to investigate 1) the
short- and long-term effect of intravenous nitroglycerin on
peripheral arteries, veins and microcirculation in humans,
and 2) whether simultaneous infusion of N-acetylcysteine
and nitroglycerin affects the response to nitroglycerin in
these vascular beds
. In addition, the effects of an interven-
tion with N-acetylcysteine after prolonged nitroglycerin in-
fusion are examined .
0735-1097/941$6 .00
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The study group comprised eight healthy male volunteers
who were taking no medication ; the mean age was 30 years
(range 25 to 42) . Electrocardiograms and physical examina-
tions were normal in all subjects . Informed consent was
obtained from all participants, and the study was approved
by the Scientific Ethical Committee of Copenhagen .
The investigation was performed as a double-blind, ran-
domized, crossover trial . Period A consisted of 24 h of
nitroglycerin infusion . N-acetylcysteine was coinfused dur-
ing the 1st 23 h . When the N-acetylcysteine infusion was
terminated (at 23 h), a placebo bolus infusion was given . Period
B consisted of 24 h of nitroglycerin infusion with placebo
coinfused during the 1st 23 h . When the placebo infusion was
terminated, a bolus infusion of N-acetylcysteine was given . All
subjects received treatments A and B in random order sepa-
rated by a 1-week washout interval . Thus, the study consisted
of a nitrate tolerance preventive period (the 1st 23 h) and a
nitrate tolerance interventional period (from 23 to 24 h) . Nitro-
glycerin was administered as an intravenous infusion at a dose
of 0.1 gg/kg per min . N-acetylcysteine coinfusion was given at
a dosage of 2 g over 15 min, followed by 5 mg/kg per h (in 0 .9%
saline solution). The bolus infusion of N-acetylcysteine con-
sisted of 100 mg/kg (in 100 ml 0.0 saline solution) over 15 min.
The nitroglycerin dose of 0 .1 pgtkg per min was chosen
because preliminary experiments showed that this dose in-
duced significant changes in arterial diameters with only sub-
maximal venodilation, thus allowing detection of a further
N-acetylcysteine-induced change in both of these investigative
variables. The continuously infused dose of N-acetylcysteine
has previously been reported (11) to modify tolerance devel-
opment to the anti-ischemic effect of nitrates
Studies were carried out in a warm quiet environment .
Hemodynarnic measurements were performed immediately
before the start of infusions (pretreatment, 0 h, between I I
and 12 AM) and repeated after 1 h (short-term), after 23 h
(long-term) and after 24 h of nitroglycerin infusion (after the
N-acetylcysteine/placebo bolus infusion) . At each time
point, measurements were performed after j2 h of supine
rest .
Hemodynan* measurements . Venous volume measure-
ment technique . Changes in venous tone were evaluated by
measuring changes in venous volume (miM ITI g) by the
plethysmographic equilibration technique, employing a mer-
cury-in-Silastic strain gauge (10,17) . The calf was placed
above the level of the heart and the strain gauge was placed
at the calf site with the largest circumference. An ankle cuff
was inflated to 200 mm Hg to isolate the foot from the
circulation . A venous occlusion cuff was placed immediately
below the knee and inflated to 30 mm Hg above the pressure
where calf volume started to increase . The increase in
venous volume reached a plateau after 3 to 4 min, and this
value was considered to represent venous volume (m11100 g
calf) at each investigative time point .
Lower limb bloodflow measurement technique . Subjects
were instrumented as just described . The total arterial calf
blood flow was calculated from the initial rate of change in
calf volume occurring after a rapid inflation of the venous
occlusion cuff (to approximately 50 mm Hg) and is reported
as mY100 g calf/min (18) . Three to five flow determinations
were measured and averaged . Calf vascular resistance was
calculated by dividing mean arm arterial pressure by calf
blood flow .
Systemic blood pressure and heart rare ineasuremems .
Systolic blood pressure, diastolic blood pressure and heart
rate were measured every 15 min throughout the study
period using an automatic, portable blood pressure recorder
(Takeda Medical, A & D Co., Japan) .
Subcutaneous blood flow measurement technique . Sub-
cutareous blood flow was measured approximately 10 cm
abov ,: the knee on the lateral part of the thigh with the
xenon-133 washout technique (19) . The tracer (xenon-133)
was applied epicutaneously and a portable semiconductor
detector was fixed directly on the labeled skin surface by
adhesive tape. The measurements were begun 90 min after
the labeling procedure, allowing time for the lipophilic tracer
to be deposited in the subcutaneous fat . Subcutaneous
xenon-133 washout rate constants were recorded continu-
ously in a portable data storage unit (Memolog System 600,
Simonsen Medical, Randers, Denmark) . Absolute subcuta-
neous blood flow (SBF) was calculated from . SBF = A x
k x 100 ml/min per 100 g, where A denotes the tissue to blood
partition coefficient for xenon-133 (10 ml/g) in subcutaneous
tissue. In the present situation, A may be considered to be
constant throughout the study periods. Thus, changes in the
washout rate constant (k), which is calculated front the
xenon-133 disappearence curve, reflect microcirculatory
changes in subcutaneous blood flow . Subcutaneous vascular
resistance was calculated by dividing mean arterial pressure
by the subcutaneous blood flow .
Arterial diameter measurement technique . Diameters of
the temporal and radial arteries were measured with a high
resolution, real time ultrasound technique (Dermascan C,
Cortex Technology, Hadsund, Denmark) . High frequency
(20 MHz; bandwidth 15 MHz) ultrasound was directed
perpendicular to the skin and the artery was located . Mea-
surements were made at the right frontal branch of the
superficial temporal artery and at the radial artery at the right
wrist. Day to day positions of measurements were repro-
duced by recording the scanning position in relation to the
angle and distance relative to the orbitomeatal line (temporal
artery) and to the distal volar crest Gf the wrist (radial
artery) . To augment precision, data are presented as a mean
of four measurements performed within 15 s . Details of this
method have been described previously (20) .
Statistics. Comparison of variables over time on each test
day were performed by a repeated measures analysis of
variance. Comparisons of the measured variables at each
time interval on N-acetylcysteine and placebo days were
made by Student t test . Results are expressed as mean value
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Table 1 . Hemodynamic Effects of Nitroglycerin Plus N-Acelylcysleine iii AC} and Nitroglycerin Plus Placebo iPu infusion for 23 Hours
in Eight Healthy Human Volunteers and Results From a Subsequent Bolus Infusion of N-Acetylcysieine or Placebo at 24 Hours
p < 0.05 compared with pretreatment values ;
Pretreatment (0 h)
± SEM. For all analyses, a p value < 0 .05 was considz:red,
significant .
ReScAts
Vascular changes during prolonged coinfusion of nitroglyc-
erin and N-acetylcysteine . Baseline hemodynarnic values at
each investigative time point are presented in Table 1 . None
of the pretreatment values differed significantly between the
two study periods (p > 0.05) .
Subcutaneous blood flow and vascular resistance . Subcu-
taneous blood flow was not significantly affected by infusion
of nitroglycerin plus placebo (Table 1, Fig . 1) . In contrast,
nitroglycerin plus N-acetylcysteine infusion resulted in a
marked increase in subcutaneous blood flow after I INP < 0 .05)
(Table 1, Fig . 1) . Although significantly attenuated, this effect
was still present after 23 h of infusion (Table 1, Fig . 1) . This
response to nitroglycerin plus N-acetylcysteine is significantly
different from the response to nitroglycerin plus placebo (p <
0.05). Similarly, the calculated subcutaneous vascular resis-
tance was significantly lower throughout the infusion of nitro-
glycerin plus N-acetylcysteine as compared with nitroglycerin
plus placebo (p < 0.05) (Fig. 1)
Changes in venous volume
. Nitroglycerin plus placebo
caused a significant increase in venous volume after I h .
However, this effect was lost after 23 h (Table 1, Fig . 2),
suggesting development of tolerance . In contrast, nitroglyc-
erin plus N-acetylcysteine induces a significant increase in
venous volume as compared with the infusion of nitroglyc-
erin plus placebo (Table 1, Fig . 2) . This effect is also present
after 23 h of treatment (Table 1, Fig . 1, suggesting a preserved
action of nitroglycerin on the venous vascular bed .
Ari',-rial diameter changes . Diameters of
the radial and
temporal arteries were significantly increased after 1 h of
infusion on both study days (Table 1, Fig
. 2) . A clear trend
toward attenuation of this effect during the infusion periods
did not reach statistical significance (p > 0 .05) and a signif-
nOESGAARD ET AL .
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23 h After Bolus Inhain (24
h)
< 0.05 compared with placebo : tp < 0 .05 compared with 23
Data are mean value ± SEM .
icant increase in diameters was still present after 23 h as
npared with pretreatment values . No indication of an
effect of nitroglycerin plus N-acetylcysteine infusion on
arterial diameters as compared with nitroglycerin plus pla-
cebo was observed (Table 1, Fig . 2) .
Calf blood fast' and vascular resistance . Neither nitro-
glycerin plus placebo nor nitroglycerin plus N-acetylcysteine
infusion significantly influenced total calf blood flow (Table
1 . Fig . I). Because mean arterial pressure did not change
during the study, the calculated calf vascular resistance was
not significantly affected by either treatment .
Heart rate and blood pressure . A small but signif cant
(p < 0.05) reduction in systolic blood pressure was observed
after I h of infusion (nitroglycerin plus placebo, from 117 ±
2 to 114 ± 2 mm Hg; nitroglycerin plus N-acetylcysteine,
from 119 ± 6 to 115 ± 6 mm Hg). These changes were
maintained throughout the study period without any signifi-
cant treatment difference (p > 0 .05). A trend toward reduced
mean arterial blood pressure did not reach statistical signif-
icance (Table I) . Heart rate was significantly (p < 0 .05)
increased after I h (nitroglycerin plus placebo : from 58 ± 3
to 70 ± 3 beats/min ; nitroglycerin plus Ar-acetylcysteine :
from 57 ± 3 to 71 ± 5 beats/min, p < 0 .05) (Table I) .
Changes in heart rate were similar in both treatment periods
and were maintained throughout the 23-h infusions .
Vascular changes after N-acetyleysteine bolus infusion after
intravenous nitroglycerin infusion for 23 h . After 23 h of
nitroglycerin plus placebo infusion, a bolus infusion of
N-acetylcysteine (100 mg/kg over 15 min) significantly in-
creased calf blood flow (from 2 .84 ± 0
.12 ml/100 g per min
to 3 .21 ± 0.19
Inilloo g per min, p < 0 .05) (Table 1, Fig . 3)
and lowered calf vascular resistance (from 31 .0 ± 0
.72 to
27.1 ± 0.8
mm 4giral per 100 g/min, p < 0.05). When
N-acetylcysteine was coinfused during the first 23 h of the
24-h nitroglycerin infusion, termination of N-acetylcysteine
infusion and subsequent placebo bolus administration re-
sulted in a significant decrease in calf blood flow (from
Subcutaneous blood flow P 3 .0 = 0 .6 j t 0 .3 3 .1 ± 0 .5 NAC
Iml,11W g per rnull NAC 31 0 3 3 l0tf 4.4 t OV -! P
Radial IOU wmnci P 3 .50 ' 0 .13 3 .33 ± 0 .16' NAC 3 .20 117 ,
(mm) NAC 2 .7 0 .11 3.24 0 .12- P 3 .07 0 .12'
Temporal artery diameter P 1 .14 0 .10 1 .55 0 .13* 130 1 0 .06* NAC 1 .23 0 .07*
(MM) N AC 1 .20 0 .08 163 0 .11 , 135 0 .09` P 1 .31 0 .04"
Venous volume P 3 .24 0 .42 3 .65 O.W 3 .47 0 .41 NAC 4 .26 0.41*t
(MI/100 8) NAC 3 .44 0 .26 4.45 0 .36* -; 4 .35 C .25- 4 P US 0.34*
Calf blood 901V P 2 .68 0 .34 2 .90 0 .29 2 .84 0,12 NAC 3 .21 0.19*1
(MV160 g per min) NAC 2 .84 0 .35 2 .94 0 .19 3 .35 0 .32 P 2 .80 0,25--ir
Mean arterial blood pressure P 8542 82}1 84 2 NAC 83 3
(mm Hg) NAC 84 3 83±2 P 84±4
Heart rate (beatslmin) P 583 70 t 3' 66 4* NAC 66 5
NAC 57-3 71-_5' 6() 5 * P 69±5
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Figure 1 . Mean changes (± SEM) in subcutaneous blood flow
(SBF), subcutaneous vascular resistance (SVR) and total calf blood
flow (CBF) after I and 23 It of intravenous infusion of nitroglycerin
plus placebo (dashed lines) and nitroglycerin plus N-acetylcysteine
(solid lines) . Values are expressed as change from pretreatment
(0 h) in eight healthy male volunteers . I, p < 0 .05 compared with
pretreatment ; 2, p < 0 .05 compared with nitroglycerin plus placebo .
3 .35 ± 0 .32 to 2 .80 ± 0.25 mm Hg/ml per 100 g/min, p < 0 .05)
(Table 1, Fig . 3) .
N-acetylcysteine bolus administration significantly in-
creased venous volume from 3 .47 ± 0.41 to .26 ±
0.41 ml/100 g, p < 0 .05) (Table 1, Fig. 3) . For technical
reasons, the effect of N-acetylcysteine bolus administration
on subcutaneous blood flow was not investigated . Arterial
diameters and other variables were not affected by N-
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(a. temp .) artery diameters and venous volume after I and 23 h of
intravenous infusion of nitroglycerin plus placebo (dashed lines) and
nitroglycerin plus N-acetylcysteine solid lines) . Values are ex-
pressed as change from pretreatment (0 h) in eight healthy male
volunteers . l, p < 0 .05 compared with pretreatment ; 2, p < 0.05
compared with nitroglycerin plus placebo .
acetylcysteine plus placebo bolus administration (p > 0 .05)
(Table 1) .
•
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The present clinical study provides new information
about the peripheral vascular effects of intravenous coad-
ministration of N-acetylcysteine and nitroglycerin in the
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Figure 3 . Individual changes in calf blood flow (top) and venous
vascular volume (bottom) after 1) a bolus infusion of N-aeelylcys-
teine (NAG) (100 mg/kg) after infusion of nitroglycerin (NTG) (0 .1
µg/kg per min) for 23 h, and 2) a bolus infusion of placebo (saline
solution) after infusion of nitroglycerin plus N-acetylcysteine for
23 h in eight healthy male volunteers . The nitroglycerin ;, nfusion was
continued during N-acetylcysteine/placebo bolus administration .
prevention of nitrate tolerance and about the interventional
use of thiol donors after the development of tolerance . First,
continuous N-acetylcysteine infusion potentiates and pre-
serves nitroglycerin-induced venodilation and increases sub-
cutaneous blood flow (which is mainly regulated by small
precapillary resistance vessels) while having no effect on
larger arteries . Second, a high dose of N-acetylcysteine
increases peripheral blood flow and the venodilator capacity
of nitroglycerin after development of tolerance .
Effects of nitroglycerin. In addition to its short-term (1-h)
venodilator properties, nitroglycerin increases the radial and
temporal artery diameters without affecting subcutaneous or
total calf blood flow and vascular resistance . A similar
heterogeneous arterial sensitivity to nitroglycerin has been
described in the coronary circulation (21,22), and together
the results suggest that the short-term effect of nitroglycerin
may be qualitatively similar in the coronary and systemic
arterial vascular beds . After 23 h of nitroglycerin infusion,
BOESGAARD ET AL .
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the effect on the venous vascular bed was lost, whereas an
attenuated but significant effect on arterial diameters w :-)-s
still present . This finding is in agreement with previous
reports (13,17 .23) on both venous tolerance development
and the rate of venous versus arterial tolerance appearance
in patients without congestive heart failure . suggesting that
within the 1st 24 h, tolerance to nitroglycerin develops
pred minantly on the venous side of the circulation, Thus, it
is possible that the normal balance between nitroglycerin-
mediated preload and afterload ef fects is changed during the
development of tolerance in humans .
Effects of nitroglycerin plus N-acetylcysteine- The metab-
olism of nitroglycerin requires interaction with ihiols such as
cysteine and glutathione at one or more steps in the biotrans-
formation to vasoactive nitrosothiols or nitric oxide (4,5,24) .
High doses of thiol donor compounds, (for example, N-
acetylcysteine) do not have intrinsic hemodynamic effects
either in the coronary (6,9,15,16) or syste is (7,8,10,24,25)
circulation . However, combined with nitroglycerin, thiols
significantly potentiate the vasodilator properties of nitro-
glycerin (6 W,15,16,24) . At present, it is not known whether
this interaction is due to a general potentiation of ail the
vascular effects of nitroglycerin or whether N-acetylcysteine
modifies the vasodilator responses to nitroglycerin differ-
ently in various parts of the circulation . However, thiol
administration to the coronary circulation of dogs primarily
enhances the effect of nitroglycerin in small resistance
vessels not normally sensitive to nitroglycerin, suggesting
that thiols may change the vasodilator characteristics of
nitroglycerin (15,16) .
The present clinical results show that N-acetylcysteine
also modifies the effect of nitroglycerin in peripheral micro-
circulatory vascular areas . This effect is revealed in the
acute and (to a lesser degree) chronic increase in subcuta-
neous blood flow as measured with the xenon-133 washout
technique. Because blood flow in this microcirculatory re-
gion is mainly regulated by precapillary small arterioles, the
results strongly suggest that N-acetylcysteine, as in the
coronary circulation, enhances nitroglycerin effects on small
peripheral resistance vessels .
Total calf blood flow decreased during the last hour of
nitroglycerin infusion (after termination of N-acetylcysteine
infusion) (Fig . 3, placebo), favoring some degree of N-
acetylcysteine-mediated flow change during the nitroglyc-
erin plus N-acetylcysteine infusion period
. This effect was,
however, not reflected in measurements of total calf blood
flow at I and 23 h . Thus, despite the effect on subcutaneous
blood flow, N-acetylcysteine concentrations (during infusion
of 5 mglkg per h) may be below the threshold for alterations
of arteriolar tone in quantitatively more important vascular
beds ; that is, skeletal muscle (preliminary data, unpublished
observation) . The finding that total calf blood Row increases
only after the N-acetylcysteine bolus administration (100 mg/kg
per 15 min) may support this hypothesis and is compatible with
a previous report (8) of a dose-dependent effect of thiol
supplementation on nitroglycerin hemodynamics . Alterna-
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tively, N-acetylcysteine-mediated effects on vascular resis-
tance may be subjected to powerful central or peripheral
counterregulatory mechanisms (26) .
The effect of continuous N-acetylcysteine infusion on the
venous vascular bed includes a potentiation of the short-
term (I-h) response to nitroglycerin and a preservation of
nitroglycerin effect throughout the study period . In addition,
as previously reported (10,13), N acetylcysteine bolus ad-
ministration increased venodilation after development of
venous tolerance. Both findings are in agreement with in
vitro results of increased venous sensitivity to nitroglycerin
after incubation with cysteine (12) . Whether the effect of
thiol compounds on nitrate responsiveness after the devel-
opment of tolerance represents a reversal of tolerance or a
tolerance nondependent nitrate/thiol interaction is currently
not clear. However, the effect of N .-acetylcysteine bolus
administration is short-lived (14,27) and, from a practical
point of view, preventive infusion of lower doses of thiol
compounds may be a more rational approach .
Medium-sized arteries dilate in response to nitroglyc-
erin in vitro, but N-acetylcysteine administration appears
have no or minor influence on this response (12) . An
N-acetylcysteine-induced dilation has previously been
reported in the temporal artery in vivo, whereas dilation
of the radial artery (25) and large epicardial coronary
arteries (28) seems unaffected by N acetylcysteine adminis-
tration. In the current study, we were not able to detect any
N-acetylcysteine-related potentiation of the nitroglycerin-
induced increase in radial and temporal artery diameters
after short-term (1-h) and prolonged (23-h) exposure to
nitroglycerin plus N-acetylcysteine or after N-acetylcysteine
bolus administration .
It is not known why the venous and arterial circulation
may have different potential for tolerance development and
nitratelthiol interactions . There may be differences in the
metabolic pathways (enzymes) and the ability of nitrate/thiol
compounds to induce nitric oxide . In addition, a differential
arterial and venous response to nitroglycerin (and continu-
ous N acetylcysteine infusion) is compatible with the con-
cept of a different vascular reactivity to nitroglycerin, de-
pending on the vascular basal nitric oxide sensitivity and
nitric oxide production (29) . According to this hypothesis,
the amount of nitric oxide and nitrosothiols produced from
nitroglycerin may have a smaller hemodynamic potential in
the arterial vascular bed because of decreased arterial sen-
sitivity to nitric oxide as compared with the venous circula-
tion. Assuming that tolerance follows reduced metabolic
conversion of nitroglycerin to nitric oxide, tolerance may
initially be detected in the vascular segments with the
highest sensitivity to nitric oxide (that is, veins) . Further-
more, because of the significant basal nitric oxide production
in arteries (but not in veins), the relative increase in arterial
nitric oxide after N-acetylcysteine administration may be of
less significance .
On the basis of this hypothesis, it is interesting to speculate
that N-acetylcysteine potentiates the vascular effects of nitro-
JACC Val . 23 . No. I
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glycerin by two mechanisms. The effect of a general "nods
cific" mechanism (for example, extracellular thiol/nitrate inter-
action and nitric oxide production) depends on the sensitivity
to nitric oxide in different vascular beds and consequently
primarily augments venodilation, whereas only high doses of
N-acetylcysteine and nitroglycerin may significantly influence
vascular resistance . A "specific" mechanism involves dilation
of small resistance vessels only responsive to nitroglycerin in
the presence of exogenous cysteine . This effect may specifi-
cally enhance myocardial blood flow and increase the effects of
nitroglycerin on afterload, thus changing the vasodilator profile
of nitroglycerin.
The combined effect of these mechanisrtts is compatible
with many of the published observations, which show that
thiol supplementation, tolerance independently, may in-
crease the action of nitroglycerin on coronary blood flow
(6,9,15,16), venous vascular volume (10) and systemic blood
pressure (7,8,24) . However, not all data are consistent
(28,30,31), and the significance of nitrate/thiol interactions
probably depends on the experimental design, patient char-
acteristics, doses and schedules of drug administration .
Clearly, the clinical implications of the thiol/nitrate irtterac-
tions are uncertain . Concern has been given to the possibility
that coadministration of nitroglycerin and thiols may lead to
an undesirable dilation of small -oronary resistance vessels,
producing a coronary steal phenomenon in patients with
ischemic heart disease . However, in this respect it may be
relevant that continuous (as in the current study) or repeated
intravenous administration of N-acetylcysteine for 24 h has
previously been shown to potentiate nitrate-induced anti-
ischemic effects in patients with stable angina pectoris and to
lower the incidence of acute myocardial infarction in pa-
tients with unstable angina pectoris, respectively (11,32) .
Conclusions. This study provides the first data in humans
on the peripheral hemodynamic and vascular effects of
combined intravenous infusion of N-acetylcysteine and ni-
troglycerin in the prevention of nitrate tolerance. The results
suggest that continuous infusion of Nacetylcysteine 1) po-
tentiates and preserves nitroglycerin-induced venodilation,
2) increases subcutaneous blood flow mainly regulated by
small precapillary resistance vessels, and 3) does not affect
the response to nitroglycerin in middle-sized peripheral
arteries . Thus, continuous infusion of N-acetylcysteine en-
hances nitroglycerin-induced venodilation and may mediate
peripheral microcirculatory changes compatible with an al-
tered vasodilator profile of nitroglycerin .
We are indebted to Lene Klovgaard and Pernille Gundelach for excellent and
careful technical assistance in the laboratory .
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